In a study of spondyloarthritis patients, simultaneous increases in serum insulin-like growth factor-I (IGF-I; 15% increase from baseline, p=0.04), body weight, lean mass and bone mineral density were observed after 3 months of TNFi treatment (103). The gene discussed is IGF1; the disease is spondyloarthropathy.